|
β-lactam sterile dry powder injection
Composition:
Each Injection contains:
Cefotaxime......................................................................750
mg
Sulbuactam..................................................................1500
mg
Indications:
Used in surgical prophylaxis, meningitis, skin & soft
tissue infections like cellulitis,
chronic suppurative bacterial otits
media, cholecystitis, sexually
transmitted disease, Urinary tract
infections, infections in dialysis unit.
Description:
Cefotaxime sodium, a parenteral
cephalosporin antibiotic, exerts its
bactericidal action through inhibition
of bacterial cell wall synthesis.
Chemical structure modifications have
enabled this compound to be resistant to
the action of Richmond I, III, IV, and V
beta-lactamase enzymes.
Excellent activity against many
gram-negative bacilli, especially
Enterobacteriaceae, has been
demonstrated. Antipseudomonal activity
is generally poor, however. Activity
against gram-positive cocci, with the
notable exception of Streptococcus
fecalis, is adequate. Anaerobic activity
is variable, particularly against
Clostridia and Bacteroides species.
Acute, subacute, and chronic toxicity
studies in animals were generally
unremarkable. No mutagenic effects or
reproductive toxicity have been noted in
animals.
In man, cefotaxime is desacetylated to a
microbiologically active metabolite.
Urinary excretion is approximately
50-60% and 15-20% of a dose for the
parent compound and desacetyl
metabolite, respectively. The
elimination half-life of cefotaxime is
about one hour, with the total body
clearance being approximately twice that
of the renal clearance. Severe renal
dysfunction causes a prolongation of the
elimination half-life of cefotaxime and
particularly desacetyl cefotaxime.
A relatively low degree of protein
binding in part attributes to a wide
bodily distribution of cefotaxime.
Cefotaxime is effective in a variety of
infectious processes caused by
susceptible organisms. Local reactions
at the injection site and
hypersensitivity phenomena are the most
common adverse effects. Comparative
trials attesting to cefotaxime's
clinical utility over other parenteral
cephalosporins or amino-glycosides are
very limited. Based on the available
evidence, cefotaxime should be most
useful in combating serious
gram-negative infections, because of its
excellent activity against most of these
organisms and its low toxicity profile.
CONTRAINDICATIONS
Bactram
is contraindicated in patients who have
shown hypersensitivity to cefotaxime
sodium or the cephalosporin group of
antibiotics.
Dosage: As per
the physician’s advice.
Presentations:
MRP
Retailer Stockiest
108.00 86.40
77.76
|
